Development and validation of a GC/MS method for the determination of tadalafil in whole blood

Journal of Pharmaceutical and Biomedical Analysis

Volumn 56, Issue 3, 2011, Pages 577-581

  Nikolaou, Panagiota ^a   Papoutsis, Ioannis ^a   Athanaselis, Sotirios ^a   Alevisopoulos, Giorgos ^b   Khraiwesh, Alaa ^a   Pistos, Constantinos ^a   Spiliopoulou, Chara ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Derivatization; GC MS; Solid phase extraction; Tadalafil; Whole blood

Indexed keywords

TADALAFIL;

ACCURACY; ARTICLE; BLOOD; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG DETERMINATION; HUMAN; HUMAN TISSUE; LIQUID LIQUID EXTRACTION; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

BLOOD CHEMICAL ANALYSIS; CALIBRATION; CARBOLINES; DRUG MONITORING; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; PHOSPHODIESTERASE 5 INHIBITORS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION;

EID: 79961128319     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.05.036     Document Type: Article

References (20)

1. Zou P., Hou P., Low M.Y., Koh H.L. Structural elucination of a tadalafil analogue found as an adulterant of a herbal product. Food Addit. Contam. 2006, 23(5):446-451.
2. Hatzimouratidis K., Amar E., Eardley I., Giuliano F., Hatzichristou D., Montorsi F., Vardi Y., Wespes E. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur. Urol. 2010, 57:804-814.
3. Eardley I., Donatucci C., Corbin J., El-Meliegy A., Hatzimouratidis K., McVary K., Munarriz R., Lee S.W. Pharmacotherapy for erectile dysfunction. J. Sex. Med. 2010, 7:524-540.
4. Giannitsas K., Perimenis P. Phosphodiesterase-5 inhibitors: future perspectives. Curr. Pharm. Des. 2009, 15(30):3540-3551.
5. Costa P., Grivel T., Gehchan N. Tadalafil once daily in the management of erectile dysfunction: patient and partner perspectives. Patient Prefer. Adherence 2009, 3:105-111.
6. Falk J.A., Philip K.J., Schwarz E.R. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc. Health Risk Manage. 2010, 6:273-280.
7. Croxtall J.D., Lyseng-Williamson K.A. Tadalafil: in pulmonary arterial hypertension. Drugs 2010, 70(4):479-488.
8. Rosenzweig E.B. Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin. Pharmacother. 2010, 11(1):127-132.
9. Hasegawa T., Saijo M., Ishii T., Nagata T., Haishima Y., Kawahara N., Goda Y. Structural elucidation of a tadalafil analogue found in a dietary supplement. J. Food Hyg. Soc. Jpn. 2008, 49(4):311-315.
10. Zou P., Oh S.S.Y., Hou P., Low M.Y., Koh H.L. Simultaneous determination of synthetic phosphodiesterase-5 inhibitors found in a dietary supplement and pre-mixed bulk powders for dietary supplements using high-performance liquid chromatography with diode array detection and liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. A 2006, 1104:113-122.
11. Laties A.M. Vision disolders and phosphodiesterase type 5 inhibitors: a review of the evidence to date. Drug Saf. 2009, 32(1):1-18.
12. Shakya A.K., Abu-Awwad A.N.A., Arafat T.A., Melhim M. Validated liquid chromatographic-ultraviolet method for the quantitation of tadalafil in human plasma using liquid-liquid extraction. J. Chromatogr. B 2007, 852:403-408.
13. Cheng C.L., Chou C.H. Determination of tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection. J. Chromatogr. B 2005, 822:278-284.
14. Strano-Rossi S., Anzillotti L., Torre X., Botré F. A gas chromatography/mass spectrometry method for the determination of sildenafil, vardenafil and tadalafil and their metabolites in human urine. Rapid Commun. Mass Spectrom. 2010, 24:1697-1706.
15. Aboul-Enein H.Y., Ali I. Determination of tadalafil in pharmaceutical preparation by HPLC using monolithic silica column. Talanta 2005, 65:276-280.
16. Gratz S.R., Flurer C.L., Wolnik K.A. Analysis of undeclared synthetic phosphodiesterase-5 inhibitors in dietary supplements and herbal matrices by LC-ESI-MS and LC-UV. J. Pharm. Biomed. Anal. 2004, 36:525-533.
17. Bogusz M.J., Hassan H., Al-Enazi E., Ibrahim Z., Al-Tufail M. Application of LC-ESI-MS-MS for detection of synthetic adulterants in herbal remedies. J. Pharm. Biomed. Anal. 2006, 41:554-564.
18. Man C.N., Nor N.M., Lajis R., Harn G.L. Identification of sildenafil, tadalafil and vardenafil by gas chromatography-mass spectrometry on short capillary column. J. Chromatogr. A 2009, 1216(47):8426-8430.
19. Guidance for Industry, Bioanalytical Method Validation, Food and Drug Administration, May 2001.
20. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, ICH harmonized tripartite guideline. Validation of Analytical procedures Text and methodology Q2 (R1), step 4 2005.